Submit Manuscript  

Article Details


PD-L1 Inhibitors for the Treatment of Prostate Cancer

Author(s):

Matteo Santoni*, Francesco Massari, Liang Cheng, Alessia Cimadamore, Marina Scarpelli, Rodolfo Montironi and Antonio Lopez-Beltran   Pages 1 - 8 ( 8 )

Abstract:


The carcinogenesis of prostate cancer (PCa) results from a complex series of events. Chronic inflammation and infections are crucial in this context. Infiltrating M2 type macrophages, as well as neutrophils and T lymphocytes, contribute to PCa development, progression and response to therapy. The preliminary findings on the efficacy of immunotherapy in patients with PCa were not encouraging. However, a series of studies investigating anti-PD-L1 agents such as Atezolizumab, Avelumab and Durvalumab used alone or in combination with other immunotherapies, chemotherapy or loco-regional approaches are in course in this tumor. In this review, we illustrate the role of immune cells and PD-L1 expression during PCa carcinogenesis and progression, with a focus on ongoing clinical trials on anti-PD-L1 agents in this context.

Keywords:

Atezolizumab, avelumab, durvalumab, immunotherapy, PD-L1, prostate cancer

Affiliation:

Oncology Unit, Macerata Hospital, Macerata, Division of Oncology, S.Orsola-Malpighi Hospital, Bologna, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Department of Surgery, Cordoba University Medical School, Cordoba



Read Full-Text article